Evidence map›Paper›PMID 41346381›Full record

ArticleFrontiers in neurology2025

Levodopa/carbidopa/entacapone versus levodopa/benserazide plus pramipexole in Chinese patients with Parkinson's disease experiencing wearing off.

Cuiyu Yu, Weiguo Liu, Aiping Gong, Min Ye, Hui Huang, Yang Zhao, Chunfeng Liu, Yijing Guo, Juping Chen, Xueling Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cuiyu YuDepartment of Neurology, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China.
Weiguo LiuDepartment of Neurology, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China.
Aiping GongDepartment of Neurology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Min YeDepartment of Neurology, BENQ Medical Center, Nanjing, Jiangsu, China.
Hui HuangDepartment of Neurology, Huaibei People's Hospital, Huaibei, Anhui, China.
Yang ZhaoDepartment of Neurology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Chunfeng LiuDepartment of Neurology, The Second Affiliated Hospital of Soochow University, Soochow, Jiangsu, China.
Yijing GuoDepartment of Neurology, Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu, China.
Juping ChenDepartment of Neurology, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu, Jiangsu, China.
Xueling ZhangDepartment of Neurology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu, China.
Xianwen ChenDepartment of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Lihua ShenDepartment of Neurology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Dan LiDepartment of Neurology, Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To compare the efficacy and safety of direct switch from levodopa/benserazide (LB) to levodopa/carbidopa/entacapone (LCE) versus LB plus pramipexole (PPX) in Chinese patients with Parkinson's disease (PD) experiencing wearing off (WO). Methods: In this multicenter, prospective, randomized, open-label, observational study, 140 patients with PD experiencing WO who had been on stable LB treatment were enrolled and randomized 3:2 to receive LCE (84) or LB + PPX (56) treatment for 8 weeks. The primary endpoint was change in the daily "OFF" time from baseline. Change in the daily "ON" time was also assessed. Treatment-emergent adverse events (TEAEs) were recorded. Results: Seventy-nine patients in the LCE group and 49 patients in the PPX group completed the study. Both LCE and PPX shortened the patients' daily OFF time significantly after 8 weeks (-1.76 ± 1.70 h, Conclusion: LCE and LB + PPX were both effective, safe and tolerable in treating patients with PD who experienced WO.

Indexed as

Chinese patientslevodopa/carbidopa/entacaponeParkinson’s diseasepramipexolewearing off

Identifiers

PMID41346381
PMCPMC12672222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.